From Pathogenesis, Epidemiology, and Genetics to Definitions, Diagnosis, and Treatments of Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013  by Schultz, Heather Y. et al.
From Pathogenesis, Epidemiology, and Genetics to
Definitions, Diagnosis, and Treatments of Cutaneous Lupus
Erythematosus and Dermatomyositis: A Report from the
3rd International Conference on Cutaneous Lupus
Erythematosus (ICCLE) 2013
Heather Y. Schultz1, Jan P. Dutz2, Fukumi Furukawa3, Mark J. Goodfield4, Annegret Kuhn5, Lela A. Lee6,
Filippa Nyberg7, Jacek C. Szepietowski8, Richard D. Sontheimer9 and Victoria P. Werth10,11
Journal of Investigative Dermatology (2015) 135, 7–12; doi:10.1038/jid.2014.316
MISSION TO DEVELOP
INTERNATIONAL STANDARDS
The 3rd International Conference on
Cutaneous Lupus Erythematosus (CLE)
was held from May 6 to 8 in Edinburgh,
Scotland, in conjunction with the Inter-
national Investigative Dermatology
meeting. Approximately 50 researchers
and clinicians representing North Amer-
ica, Europe, Asia, and Africa were in
attendance. Building on previous meet-
ings in Du¨sseldorf, Germany, in 2004
and Kyoto, Japan, in 2008, this third
conference was organized by Drs Jan
Dutz, Fukumi Furukawa, Mark Good-
field, Annegret Kuhn, Lela Lee, Filippa
Nyberg, Jacek Szepietowski, and Richard
Sontheimer and overall meeting organi-
zer Victoria P. Werth. The overarching
goals of this conference were to provide
an international forum for CLE research-
ers and clinicians to explore recent
developments in basic science and in
translational and clinical studies, to
develop approaches to allow the CLE
community to reach consensus for uni-
form definitions, diagnostic criteria, and
classification of CLE and systemic lupus
erythematosus (SLE)–associated skin
lesions, and to develop mechanisms
for ongoing international collaborations.
Furthermore, this meeting included dis-
cussions about the related autoimmune
disease dermatomyositis (DM).
Standard definitions and consensus
classification are paramount in this field
because of the current lack of standard
definitions and categorization. Develop-
ment of a standardized classification is
critical to allow for collaboration across
continents, interpretation of published
studies, and conduction of clinical trials.
To initiate the beginnings of a group
effort to develop a classification scheme,
several speakers presented background
information related to the development
of such a consensus. Dr Joseph Merola
(Harvard Medical School, Boston, Mas-
sachusetts) spoke about the Delphi tech-
nique (Dalkey and Helmer, 1963; Hsu
and Sandford, 2007). This process
involves a series of questionnaires
delivered in multiple iterations to
collect data from a panel of selected
experts in the field of CLE. This
technique has been used successfully
in the past in related fields to develop
classification criteria for systemic
sclerosis, to define outcome domains
for psoriasis, and to establish core
domains to assess flare in rheumatoid
arthritis (Bartlett et al., 2013). One
benefit of this technique is that diverse
members of the scientific community
have an equal voice in determining the
final outcome.
Drs Kari Connolly (University of Cali-
fornia San Francisco), Jo¨rg Wenzel (Uni-
versity of Bonn), Ben Chong (University
of Texas Southwestern Medical Center,
Dallas, Texas), Melissa Costner (Univer-
sity of Texas Southwestern Medical
Center), Annegret Kuhn (University of
Mu¨nster), Asad Zoma (Glasgow Univer-
sity, Scotland), Lela Lee (University of
Colorado), Richard Sontheimer (Univer-
sity of Utah), and Ingrid Lundberg (Kar-
olinska Institute, Stockholm, Sweden)
gave very informative presentations that
outlined the current thinking about cate-
gorization of lesions and described the
current and historical classification cri-
teria for CLE, SLE, and DM. In addition,
the attendees split into three groups to
discuss ideas regarding definitions, diag-
nosis, and classification. The groups
presented summaries of their unique
discussions to the whole group, prompt-
ing ample discourse among the group
members. From here, the conference
organizers plan to draw from the results
of the subgroups to establish Delphi
questionnaires, which will be filled out
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by the attendees as well as by additional
experts in the field. This meeting, there-
fore, was a first step toward the accep-
tance of a universal standard for a
definition and classification system for
CLE.
CURRENT CLIMATE OF CLE
Pathogenesis
With more than 20 oral presentations
and 11 posters (many of which are
summarized here), the current state of
research on, epidemiology of, and treat-
ment for CLE was described by well-
known experts in the field. As the role of
environmental factors in the induction
of autoimmune diseases remains
unclear, the utilization of animal models
of diseases offers a chance to examine
these effects in detail. Repeated UV light
exposure in non-obese diabetic mice
results in the induction of anti-nuclear
antibody in these animals (O’Brien
et al., 2006). Repeated topical imiq-
uimod treatment may also induce an
SLE phenotype in non-autoimmune-
prone animals (Yokogawa et al., 2014).
Dr Jan Dutz presented data showing that
treatment of non-obese diabetic mice
with repeated UV light exposure in
combination with Toll-like receptor-7
engagement with imiquimod resulted
in SLE-like disease with enhanced anti-
nuclear antibody and anti-Dsg3 antibody
production, glomerulosclerosis, and
serum IFN-a levels. The results
obtained in this animal model are in
agreement with the observed high levels
of skin-specific autoantibodies in a
subset of pediatric SLE patients (Li
et al., 2011). In addition, treatment of
mice with chloroquine prevented UV-
induced anti-nuclear autoantibody
production, supporting use of this drug
as a treatment strategy. Dr Min Ae Lee-
Kirsch (Technical University Dresden,
Germany) discussed the pathogenesis
of TREX1-associated forms of CLE. A
loss-of-function mutation in the TREX1,
a DNA exonuclease with specificity for
single-stranded DNA, was identified in
chilblain lupus. TREX1 mutations have
been identified in SLE patients in the UK
and Germany. Mice homozygous for
this mutation mount an autoimmune
response and die; however, inter-
breeding with mice deficient for the
IFN regulatory factor 3 permits survival
of these mice. This result implicates IFN
in the phenotype, consistent with IFN
activation in TREX1-associated chilblain
lupus patients. TREX1 variants confer a
high risk of SLE, perhaps due to the
accrual of intracellular nucleic acid
species and subsequent activation of
the innate immune system via type 1
IFN.
Dr Regine Gla¨ser (University of Kiel,
Germany) described the role of antimi-
crobial peptides in CLE. Because skin
infections are rarely observed in CLE
patients or psoriasis patients and psor-
iasis lesions contain high levels of anti-
microbial peptides, it is not surprising
that antimicrobial peptides, including b-
defensins 2 and 3, cathelicidin LL-37,
and psoriasin, are significantly induced
in CLE skin compared with the skin of
healthy controls (Kreuter et al., 2011).
On the other hand, these antimicrobial
peptides serve as immune system
alarmins, and thus may not be ideal in
an autoimmune environment and may
even be pathogenic (Harder et al., 2013).
Epidemiology
Dr Mark Davis (Mayo Clinic, Rochester,
Minnesota) reported the results of a
population-based study of 156 CLE
patients from 1965 to 2005 from the
Rochester Epidemiology Project data-
base of patient records from Olmsted
County, Minnesota. Incidences of 4.30
cases of CLE, 3.56 cases of classic
discoid LE (DLE), 0.63 cases of subacute
CLE (SCLE), and 0.07 cases of lupus
erythematosus panniculitis per 100,000
person-years were calculated (Durosaro
et al., 2009). These values were similar
to previously published incidences of
SLE, and thus CLE is nearly as
common as SLE. Approximately 12%
of CLE cases progressed to SLE. Dr
Fukumi Furukawa described the results
of genome-wide association studies to
determine the epidemiology of the
subtypes of CLE in Asia and
highlighted the differences between
Asian and Caucasian populations. SCLE
is rare in Asia, likely because of the lack
of the genetic HLA-DR3 allele in the
population; however, this subtype
occurs more commonly in 24% of CLE
cases in Caucasians in the United States
and Europe. In contrast, Sjo¨gren’s
syndrome annular erythema is more
common in Japanese compared with
Caucasian populations. Dr Filippa
Nyberg presented the results of a
population-based cohort study of 1088
CLE patients conducted in Sweden
(Gronhagen et al., 2011). The
incidence of CLE was found to be 4
per 100,000. Approximately 80% of
cases were DLE, 15.7% were SCLE,
and 4.5% were of other subtypes.
More than 10% of DLE cases
progressed to SLE within a year, and
more than 20% of SCLE patients
progressed to SLE within 1 year. In
another study of drug-induced SCLE,
more than 38% of cases were found to
be associated with an exposure to drugs
within 6 months of diagnosis; however,
the absolute risk of developing SCLE
from a medication is small (Gronhagen
et al., 2012). Dr Annegret Kuhn
presented the suggested ‘‘Duesseldorf
Classification’’, which was published in
the context of the first ICCLE 2004 in
Duesseldorf, Germany, including lupus
erythematosus tumidus (LET) as the
intermittent subtype of CLE (ICLE)
(Kuhn and Lehmann, 2004). In
addition, Dr Annegret Kuhn delivered
an update on the European Society of
Cutaneous Lupus Erythematosus
(EUSCLE) and the core set question-
naire, which was originally published
in 2009 with the aim to contribute to
standardized assessment and monitoring
of CLE and to develop diagnostic and
therapeutic guidelines (Kuhn et al.,
2009). Since then, 1002 patients from
30 centers in 14 countries have been
included in the database, documenting
the clinical subtypes of this disease
(acute CLE 30.3%, SCLE 23.6%,
chronic CLE 39.6%, and intermittent
CLE 6.5%) (Biazar et al., 2013).
Recently, a consecutive study evalu-
ated the preventive and therapeutic
strategies used for these patients (Sigges
et al., 2013). Sunscreens were applied
by 84.0% of the study cohort and
showed an overall efficacy of 94.7% in
the prevention of skin lesions.
Topical steroids were used in 81.5%
of the CLE patients, with an efficacy of
88.4%, whereas systemic drugs, such as
antimalarials, and several immunomo-
dulating/suppressive drugs, including
systemic steroids and methotrexate,
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were applied in 84.4% of the 1002
patients.
Treatment
Dr Sue Jessop (University of Cape Town,
South Africa) gave a thorough summary
of the current CLE treatment options and
the quality of the available evidence for
each option. Although much of the
evidence stems from case reports,
uncontrolled studies, and short trials,
physician experience in clinical practice
adds perspective and has been impor-
tant in determining treatment appro-
aches (Jessop et al., 2009).
Dr Thomas Ruzicka (University of
Du¨sseldorf, Germany) presented an
overview of current topical treatment
strategies for CLE. Although corticoster-
oids are often the first-line treatment for
CLE and are often very effective, case
reports and a multicenter randomized
controlled trial using tacrolimus 0.1%
ointment have suggested that the calci-
neurin inhibitors may be a good alter-
native in patients who do not respond to
corticosteroids or in those in whom
corticosteroids are contraindicated
(Kuhn et al., 2011). This drug has
several advantages, including rapid
onset, safety during long-term use, few
side effects, and low risk for infections
and lymphoma; however, tacrolimus
ointment is more expensive, has lower
overall efficacy compared with cortico-
steroids, and may induce troublesome
local side effects.
Antimalarials have been used to treat
symptoms of CLE and SLE for decades,
as these drugs modulate the immune
system without predisposing patients to
infection. Dr Camille Frances (Hoˆpital
Tenon, Paris, France) chronicled the
evidence for first-line systemic treat-
ment of CLE with these agents. A study
of 300 patients with CLE demonstrated
that higher blood levels of hydroxy-
chloroquine were associated with effi-
cacy (Frances et al., 2012).
Unfortunately, hydroxychloroquine is
associated with ocular toxicity (0.4%),
and skin pigmentation is a troubling
side effect of long-term use (Jallouli
et al., 2013). Changing the anti-
malarial drug used for treatment did
not lead to relapse of disease in a
report on several patients. Dr Elisabeth
Aberer (Medical University of Graz,
Austria) described the use of dapsone
and retinoids as second-line treatments
for lupus for CLE. Dr Aberer’s group
performed a retrospective study of
dapsone treatment on 34 patients with
CLE previously treated unsuccessfully
with chloroquine or hydroxychloro-
quine. Fifty-eight percent of these
patients exhibited healing or improve-
ment of cutaneous lesions. All tested
subtypes of CLE (DLE, SCLE, LET, and
SLE) responded, and only four patients
required discontinuation of medication
because of adverse reactions. Retinoids,
including etretinate, acitretin, and iso-
tretinoin, have exhibited good efficacy
in the treatment of DLE, SCLE, CLE, and
SLE patients in case series and small
studies. Dr Werth noted an 80–90%
overall response rate to thalidomide in
SCLE and DLE; however, a high relapse
rate (up to 70%) and a high incidence of
neurotoxicity have spurred additional
investigation into potentially less neuro-
toxic thalidomide analogs such as lena-
lidomide. Although abetacept has not
demonstrated reliable efficacy in pla-
cebo-controlled trials, the anti-B lympho-
cyte stimulator antibody belimumab was
shown to reduce SLE activity scores and
was approved for use in refractory SLE
cases. Additional work on the use of this
drug for CLE is warranted.
Dr Miriam Wittman (University of
Leeds, United Kingdom) noted that a
high percentage of patients with SCLE
and DLE exhibited vitamin D deficiency
or insufficiency. CLE patients were
observed to have low vitamin D levels
in both summer and winter, whereas
healthy individuals exhibited an
increase in summer months (Renne
et al., 2008). These findings are
plausibly explained by photoprotection
combined with inadequate vitamin D
supplementation. Vitamin D provides a
myriad of functions in cellular growth
and immune function, and low levels of
vitamin D were found in CLE patients
with higher IFN levels, indicating higher
disease activity. Thus, vitamin D
supplementation may be beneficial for
these patients. A recent study showed
that SLE patients exhibited higher vitamin
D levels, lower disease activity scores,
and decreased anti-DNA antibody levels
following vitamin D supplementation
(Terrier et al., 2012).
Dr Goodfield presented a study on
the use of stem cell therapy to treat SLE.
Stem cell transplantation, mainly hema-
topoietic stem cell transplantation, has
been used successfully to treat SLE
patients with life-threatening disease;
however, no data specific to skin man-
ifestations have been reported. This
treatment regime carries high mortality
risk but can be effective in disease
control despite risks of relapse, second-
ary autoimmune disease, and malig-
nancy. Indeed, one study of 28 SLE
patients treated with stem cell transplan-
tation indicated a 5-year-survival rate of
81% and a relapse incidence of 56%.
More recently, use of multipotent
mesenchymal stem cells from umbilical
cord blood cells has been investigated as
a means of transplant therapy, as these
cells have low immunogenic potential
and can be delivered locally or systemi-
cally. Studies in 2010 and 2012 on
patients with life-threatening SLE indi-
cated great promise for this therapy as
clinical remission (28% at 1 year and
50% at 4 years) was achieved in many
patients with low relapse (0–23%) and
there was no treatment-related mortality
or severe adverse effects.
Dr Simon Meggitt (Newcastle Univer-
sity, United Kingdom) presented data
demonstrating that current smokers had
a significantly higher risk for SLE/CLE
and higher disease activity scores com-
pared with either ex-smokers or those
who never smoked, and current smokers
also exhibited a higher frequency of
anti-dsDNA autoantibodies compared
with those in the other groups. Smoking
has also been specifically associated
with cutaneous manifestations in SLE.
At least two recent studies have demon-
strated that smoking does not have an
effect on the response of CLE patients to
antimalarials.
Treatment of CLE is based primarily
on personal experience. Dr Jacek Sze-
pietowski described the results of a
survey of dermatologists from 51 clinics
in Japan, the United States, and Europe
to ascertain the current practice varia-
tion in CLE therapy. Results of these
surveys described extreme variation in
treatment modalities, treatment of the
different subtypes, use of topical versus
systemic therapy, the length of time
before modification of therapy, and
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parameters used to assess efficacy in
CLE treatment. For example, 14% of
the dermatologists reported that sys-
temic treatment was offered to CLE
patients immediately, whereas 18%
offered this therapy after one topical
treatment failure, 33% offered this ther-
apy after two topical treatment failures,
14% offered this therapy after three
topical treatment failures, and 4% never
offered this treatment option. In addi-
tion, 33% of the dermatologists assess
CLE activity at each visit, but 6% only
assess disease activity every 6 months.
These findings underscore the need for
expert consensus on definitions and
classification as well as the need for
multicenter clinical trials using contem-
porary methodology in order to improve
patient care standards globally.
DESCRIBING THE DETAILS OF DM
Pathogenesis
Dr Manabu Fujimoto (Kanazawa Uni-
versity, Japan) described an autoanti-
body-based classification of DM based
on Japanese studies. Approximately
75% of DM patients are positive for
myositis-specific autoantibodies, includ-
ing antibodies to synthetase, Mi-2,
MDA5, and Transcriptional Intermedi-
ary Factor 1 in the muscle fibers. In
addition, Nuclear Matrix Protein-2 and
subunits of the small ubiquitin like
modifier activating enzyme (SAE) anti-
bodies have been identified in some of
the remaining patients. Myositis-specific
autoantibody profiles have been asso-
ciated with distinct clinical subsets and
appear to be useful in the diagnosis and
classification of DM. According to
recent studies these autoantigens are
ubiquitously expressed in everyone,
but the expression of these antigens is
upregulated in certain circumstances
(Casciola-Rosen et al., 2005; Mammen
et al., 2009; Tsai et al., 2010; Yokoe
et al., 2010). For example, the Jo-1
antigen, HisRS, and Mi-2 are expressed
at low levels in normal muscle but at
high levels in myositis muscle or
regenerated muscle. In addition, it is
noteworthy that Transcriptional Inter-
mediary Factor 1 antigens, which are
predominantly targeted in cancer-asso-
ciated DM, are overexpressed in some
cancer tissues. Thus, overexpressed
autoantigens may have a role in
amplifying autoimmune responses that
target muscles and related tissues. Dr
David Fiorentino (Stanford University,
Palo Alto, California) reported that most
(83%) cancer-associated DM patients
had antibodies to either Nuclear Matrix
Protein-2 or Transcriptional Intermediary
Factor 1g, and thus the absence of these
autoantibodies was strongly predictive of
a lack of cancer in DM patients. More
specifically, Nuclear Matrix Protein-2
autoantibodies predicted male patients
with cancer (Fiorentino et al., 2013).
Importantly, an autoantibody profile for
all of these antigens indicated the clinical
phenotype for 85% of DM patients in the
United States, suggesting the clinical
relevance of such a profile.
Dr Naoko Okiyama (Tokyo Medical
and Dental University, Japan) described
a murine model of autoimmune myositis
induced by immunization with muscle-
specific antigens. The skeletal C-protein-
induced myositis model, which is super-
ior to common mouse models of this
disease because of the ability to induce
the disease in a B6 genetic background
and the fact that the disease mimics
muscle injury observed in polymyositis,
suggests that muscle-specific CD8 T
cells mediate cytotoxicity that is respon-
sible for muscle fiber injury in these
animals. In these mice, development of
autoimmune myositis requires not only
autoreactive T cells but also activation
of innate immunity in the muscle fibers.
Translational research using the C-pro-
tein-induced myositis model suggested
that blockade of inflammatory cyto-
kines, such as IL-6, IL-1, or tumor
necrosis factor-a, may be effective treat-
ments for autoimmune myositis
(Sugihara et al., 2007, Okiyama et al.,
2009).
Epidemiology
Dr Mark Davis (Mayo Clinic) described a
population-based study of the incidence
of DM and clinically amyopathic DM.
Using data from the Rochester Epide-
miology Project for residents of Olmsted
County, Minnesotta, since 1966, esti-
mates for the incidence of DM were
9.63 per million persons, with amyo-
pathic DM accounting for 20% of cases
(Bendewald et al., 2010). Dr Minoru
Hasegawa (Kanazawa University, Japan)
discussed the characteristics of cancer-
associated DM. A high percentage of
adult DM patients (72% of those over
the age of 40 and 85% of those over the
age of 60) with malignancy had
autoantibodies that recognize Trans-
criptional Intermediary Factor 1,
suggesting the possibility that these anti-
bodies may be produced during
misdirected antitumor responses.
Dr Chia-Chun Ang (University of
Pennsylvania) described the current
understanding of lung complications in
DM, which occur in up to 46% of DM/
PM patients (Morganroth et al., 2010).
Although the presence of autoantibodies
is associated with an increased risk for
interstitial lung disease (ILD), a significant
number of myositis patients have ILD
without detectable antibodies, suggest-
ing that diagnosis and prognosis require
additional parameters.
Quality of life
Dr Saroj Verma (University of Pennsyl-
vania) described the effects of CLE and
DM on patient quality of life, which is a
critical aspect to consider in clinical
practice. As expected, on the basis of
prior studies of SLE, CLE disease activity
has a significant effect on quality of life,
whereas disease-related damage does
not have such a significant effect
(Verma et al., 2014). Quality of life as
assessed by the Skindex-29 (Chren et al.,
1997a, 1997b) and SF-36 (Quality
Metric, tools was worse for both CLE
and DM patients than for those with
other skin diseases (Goreshi et al., 2011).
In addition, the mental health measures
were lower for CLE and DM patients
than for those with myocardial
infarction, diabetes, and hypertension.
Ethnic differences were observed in
CLE patients, as African-American
patients experienced damage earlier in
conjunction with disease activity (Verma
et al., 2014). In addition, photosensitivity
and pruritus contributed to the poor
quality of life observed in the CLE and
DM patients.
Treatment
Dr Beatrix Volc-Platzer (Donauspital/
SMZ Ost, Vienna, Austria) presented
evidence for treatment options for DM.
High-dose corticosteroids are the main-
stay of treatment with up to 90% of
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patients responding favorably, despite
the lack of controlled studies. Second-
line immunosuppressants, including
methotrexate, azathioprine, and myco-
phenolate mofetil, may also be effective
in combination with corticosteroids,
with methotrexate being better tolerated
than azathioprine. Nevertheless, these
steroid-sparing agents should be intro-
duced as early as possible. Methotrex-
ate, mycophenolate mofetil, and
chloroquine, and hydroxychloroquine
are successful in controlling skin
disease—albeit after some time of treat-
ment. The antimalarials may be used
either as a single agent or as a combina-
tion treatment. In the absence of suc-
cessful control of disease with these
options, and in particular with regard
to refractory muscle disease, IVIg may
be used. Therapeutic efficacy has been
demonstrated in a randomized, con-
trolled crossover study (Dalakas et al,
1993). A more recent study to
investigate the efficacy of IVIg in 19
patients with idiopathic or
paraneoplastic DM demonstrated that
patients could be categorized into two
groups: nonresponders with higher
muscle enzyme activity, higher serum
sIL-2R levels, and severe skin and
muscle disease and responders with
lower muscle enzymes that were
reduced following treatment, lower sIL-
2R levels that decreased following
treatment, and severe skin but
moderate muscle disease. Overall, the
response rate to IVIg was 37% (Gottfried
et al., 2000). Recent promising work has
suggested that subcutaneous Ig or low-
dose IVIg may be an effective
alternative. Several open label studies
indicated that rituximab may be an
effective treatment for myositis. In
2013 the largest controlled trial was
performed in adults and children with
DM and polymyositis (Oddis et al.,
2013). Although the study did not meet
its defined outcome parameters, results
indicated that rituximab has a steroid-
sparing effect and that children may
benefit from rituximab.
CONCLUSIONS
The success of this international meeting
reflects global interest of the CLE com-
munity in developing collaborative
efforts to understand this disease and
pursuing more effective treatments.
Efforts were initiated to pursue a Delphi
technique–driven approach to consen-
sus in definitions, diagnostic criteria,
and classification. In the future, the
group plans to host a satellite meeting
at the next World Congress of Derma-
tology in Vancouver in order to con-
tinue advancement on these topics.
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